191 related articles for article (PubMed ID: 23789969)
1. Biodistribution and dosimetry of free 211At, 125I- and 131I- in rats.
Spetz J; Rudqvist N; Forssell-Aronsson E
Cancer Biother Radiopharm; 2013 Nov; 28(9):657-64. PubMed ID: 23789969
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution of free 211At and 125I- in nude mice bearing tumors derived from anaplastic thyroid carcinoma cell lines.
Lundh C; Lindencrona U; Schmitt A; Nilsson M; Forssell-Aronsson E
Cancer Biother Radiopharm; 2006 Dec; 21(6):591-600. PubMed ID: 17257074
[TBL] [Abstract][Full Text] [Related]
3. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
Larsen RH; Murud KM; Akabani G; Hoff P; Bruland OS; Zalutsky MR
J Nucl Med; 1999 Jul; 40(7):1197-203. PubMed ID: 10405142
[TBL] [Abstract][Full Text] [Related]
4. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
5. Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment.
Garg PK; Harrison CL; Zalutsky MR
Cancer Res; 1990 Jun; 50(12):3514-20. PubMed ID: 2340501
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Batra V; Samanta M; Makvandi M; Groff D; Martorano P; Elias J; Ranieri P; Tsang M; Hou C; Li Y; Pawel B; Martinez D; Vaidyanathan G; Carlin S; Pryma DA; Maris JM
Clin Cancer Res; 2022 Sep; 28(18):4146-4157. PubMed ID: 35861867
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers.
Vaidyanathan G; Boskovitz A; Shankar S; Zalutsky MR
Peptides; 2004 Dec; 25(12):2087-97. PubMed ID: 15572196
[TBL] [Abstract][Full Text] [Related]
9. Approximate distribution of dose among foetal organs for radioiodine uptake via placenta transfer.
Millard RK; Saunders M; Palmer AM; Preece AW
Phys Med Biol; 2001 Nov; 46(11):2773-83. PubMed ID: 11720346
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
11. Similarities and differences between free 211At and 125I- transport in porcine thyroid epithelial cells cultured in bicameral chambers.
Lindencrona U; Nilsson M; Forssell-Aronsson E
Nucl Med Biol; 2001 Jan; 28(1):41-50. PubMed ID: 11182563
[TBL] [Abstract][Full Text] [Related]
12. Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry.
Orlova A; Höglund J; Lubberink M; Lebeda O; Gedda L; Lundqvist H; Tolmachev V; Sundin A
Cancer Biother Radiopharm; 2002 Aug; 17(4):385-96. PubMed ID: 12396703
[TBL] [Abstract][Full Text] [Related]
13. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
[TBL] [Abstract][Full Text] [Related]
14. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.
Steffen AC; Almqvist Y; Chyan MK; Lundqvist H; Tolmachev V; Wilbur DS; Carlsson J
Oncol Rep; 2007 May; 17(5):1141-7. PubMed ID: 17390057
[TBL] [Abstract][Full Text] [Related]
16. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
Traino AC; Di Martino F; Lazzeri M
Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
[TBL] [Abstract][Full Text] [Related]
17. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
18. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
[TBL] [Abstract][Full Text] [Related]
19. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals.
Kostarelos K; Emfietzoglou D
Anticancer Res; 2000; 20(5A):3339-45. PubMed ID: 11062762
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic.
Cona MM; Koole M; Feng Y; Liu Y; Verbruggen A; Oyen R; Ni Y
Int J Oncol; 2014 Mar; 44(3):819-29. PubMed ID: 24366374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
